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Abstract
Objectives: Malaria in pregnancy is a major public health problems contributing significantly to high 
morbidity and mortality. Intermittent preventive treatment of malaria during pregnancy (IPTp) is a key 
intervention in the national strategy for malaria control, Sulphadoxine-Pyrimethamine, the current drug of 
choice, is recommended to be administered in the second and third trimesters of pregnancy during 
antenatal care (ANC) visits. Aim was therefore, to determine and compare the provision of 
chemoprevention using intermittent preventive treatment (IPTp) in public and private secondary hospitals 
in Lagos State.
Method: This is a comparative, cross sectional study that assessed the factors influencing health care 
providers - provision of chemoprohylaxis - in public and private secondary health facilities in Lagos State. 
Data was collected using a pretested questionnaires administered to 302 healthcare providers selected 
through multistage sampling. Data  generated was analysed with Epi-Info 2012 version.
Results: The private  providers had a better practice and provision of chemotherapy. Only 69.0% of public 
providers and 74.8% of private providers prescribed IPT using sulphadoxine-pyrimethamine. The private 
providers were more aware of the timing (recommended time to give IPTp) of IPTp. 
Conclusion: Both public and private health care providers have not fully embraced the evidence based 
World Health Organization  recommendation of administration of least two doses of sulphadoxine-
pyrimethamine for malaria in pregnancy.
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Chimioprophylaxie contre le paludisme - pendant la grossesse par des 
prestataires de soins publics et privés à Lagos
Resume
Objectifs: Le paludisme pendant la grossesse est un problème majeur de santé publique qui contribue de 
manière significative à la morbidité et à la mortalité élevées. Le traitement préventif intermittent du 
paludisme pendant la grossesse (IPTp) est une intervention clé dans la stratégie nationale de lutte contre le 
paludisme, la sulphadoxine-pyriméthamine, le médicament actuel de choix, est recommandée pour être 
administrée au deuxième et troisième trimestre de la grossesse pendant les soins prénatals (ANC ) Visites. 
L'objectif était donc de déterminer et de comparer la fourniture de chimioprévention en utilisant un 
traitement préventif intermittent (IPTp) dans les hôpitaux secondaires publics et privés dans l'État de 
Lagos.
Méthode: étude comparative et transversale qui a évalué les facteurs qui influencent les fournisseurs de 
soins de santé - la fourniture de chimioprophylaxie - dans les établissements de santé secondaire publics et 
privés dans l'État de Lagos. Les données ont été recueillies à l'aide d'un questionnaire prétesté administré à 
302 fournisseurs de soins de santé sélectionnés par échantillonnage multi-étapes. Les données générées 
ont été analysées avec la version Epi-Info 2012.
Résultats: les prestataires privés ont une meilleure pratique et une meilleure chimiothérapie. Seulement 
69,0% des prestataires publics et 74,8% des prestataires privés ont prescrit l'IPT en utilisant de la 
sulfatexine-pyriméthamine. Les fournisseurs privés étaient plus conscients du moment (temps 
recommandé pour donner IPTp) de IPTp.
Conclusion: Les fournisseurs de soins de santé publics et privés n'ont pas pleinement accepté la 
recommandation de l'Organisation mondiale de la santé fondée sur les preuves d'administrer au moins 
deux doses de sulfatexine-pyriméthamine pour le paludisme pendant la grossesse.
Mots-clés: Chimioprophylaxie, Malaria, Grossesse.
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INTRODUCTION
The first malaria preventive strategies 
were implemented in the 1950s. They consisted 
of weekly or bi-monthly chemoprophylaxis with 
chloroquine (CQ) in West African Countries and 
dapsone -pyrimethamine or Sulphadoxine - 
pyrimethamine (SP) in East African Countries 
(1). In 1998, it was proposed, then finally 
implemented in 2004, that chemoprophylaxis 
using daily or weekly drugs should no longer be 
recommended, but replaced by intermittent 
preventive treatment for all pregnant women 
living in areas of stable malaria transmission 
(1,2).
The control of malaria infection in 
pregnancy requires multidimensional approach. 
World Health Organization recommended 
control of malaria in pregnancy in areas of stable 
transmission through effective case management 
of malaria, -the use of intermittent preventive 
treatment of malaria in pregnancy with at least 
two doses of sulphadoxine-pyrimethamine and 
.the use of insecticide treated nets (ITNS) (3, 4)
Nigeria adopted intermittent preventive 
treatment of malaria in pregnancy (IPTp) as a 
strategy in 2005 to replace weekly prophylaxis 
(5). Unlike the prophylactic anti-malarial drugs 
that are given at less than therapeutic dose at 
regular interval that could encourage parasite 
resistance, the IPTp using sulphadoxine - 
pyrimethamine employs administration of full 
curative dose regimen at pre-defined intervals 
during pregnancy.
The drug is given irrespective of 
peripheral blood malaria parasite states and 
should be given to all pregnant women after 16 
weeks of pregnancy (6). While two doses were 
found more efficacious than single dose; some, 
studies have found that three or more doses of SP 
are more efficacious than two doses in HIV-
positive mothers (7), but no benefit was found in 
HIV-negative women (1). The treatment doses 
are given at least one month apart in the second 
and third trimesters (6). Administered at least 
twice during pregnancy regardless whether or not 
the woman has malaria and best be linked to 
routine scheduled ante-natal visits after 
quickening (1,6). The effectiveness of 
sulphadoxine - pyrimethamine in improving birth 
weight reducing prevalence of preterm deliveries 
and maternal anaemia was reported in Nigeria 
(7,8). 
The coverage of IPTp is low in Nigeria 
(6), only 18% pregnant women received an 
antimalarial drug for the prevention of malaria 
during pregnancy, 11% received at least one dose 
of SP and 7% received two or more doses (6). 
Therefore, it is necessary to assess the level of 
provision of IPTp and understand the underlying 
reasons behind the level of provision in both 
private and public health providers, 
Efforts have been made to alleviate the 
problem of malaria in pregnancy, this include the 
WHO recommendation of prompt and effective 
management of malaria in pregnancy, 
chemoprophylaxis, the use of long lasting 
insecticide nets and indoor residential spraying 
(IRS) and the use of IPTp (6,9). 
Many researchers have reported high 
prevalence rates of malaria in pregnancy in 
different parts of Nigeria, ranging 19.7% to 
72.0% (10). Also the procurement of 
antimalarials made through public health 
services increased sharply but access to treatment 
especially ACT in particular was inadequate in all 
countries surveyed in 2006 (11).  Malaria is 
responsible for 30% childhood mortality and 
11% of maternal mortality and more than 60% 
out-patient visits in Nigeria are due to malaria and 
it also accounts for 30% of all hospital admission 
with nearly 110 million cases and 300,000 deaths 
 
per year (5,6). From the above it is evident that 
access and consumption of effective intervention 
is still low and malaria in pregnancy continue to 
constitute a huge burden. 
Hence, this study was conducted to 
determine the provision and use of drugs for- 
prevention of malaria in pregnancy in public and 
private hospitals in Lagos. This can highlight 
public and private health institutions efforts in 
prevention and control of malaria in pregnancy, 
findings of which may influence policy change. 
Aim was to determine and compare the 
provision of chemoprevention using intermittent 
preventive treatment (IPTp) in public and private 
secondary hospitals in Lagos State. 
MATERIALS AND METHODS
This was a comparative cross-sectional 
study. Study population consisted of health care 
providers involved in ante-natal services in 
public and private secondary health facilities in 
Lagos State. Data was collected using a pretested 
questionnaires administered to 302 healthcare 
providers selected through multistage sampling 
at the selected healthcare facilities in the month of 
June to July, 2013. The questionnaire contained 
ques t ions  on  the  soc io-demographic  
characteristics of the respondents, facility type 
and provision of chemoprevention. Data entry 
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and analysis was done using Epi-info. 7.0.9.7 
Version. A univariate was carried out to generate 
frequencies and proportions and bivariate 
analysis to test for associations between the 
independent and the outcome variables.
The data obtained was presented as 
2tables and figures. Chi-square (X ) test was used 
to test for association between the independent 
and dependent variables at probability value 
=<0.05.
Ethical approval was obtained from 
Lagos University Teaching Hospital, Health 
Research and Ethics Committee (LUTH HREC). 
Approval for the study was also sought from the 
authorities of all selected facilities. Each 
participant signed a written informed consent 
form. 
RESULTS
A total of 302 questionnaires were 
administered, of these 290 were retrieved and 
sufficiently completed to permit detailed analysis 
giving a response rate of 96%        
Table 1 showed that the majority (84.2%) 
of the providers in the public facility were 
between the ages of 25-44years of age while a 
relatively lesser proportion (64.71%) was within 
the same age group in the private facility.
No statistically significant difference was found 
between the age of the providers in the public and 
private facility. The mean ages of providers in the 
public and private facilities were 35.08+ 7.57SD 
years and 33.97 + 10.82 SD  respectively.
Majority (71.9%) of the providers in 
public facility were married, while relatively 
lesser proportions (60.55) in the private facility 
were married. There was however a statistically 
significant difference in their marital status. The 
providers were predominantly Christians in both 
facilities (77.8% and 96.6%) with statistically 
significant difference found in their   religion. 
Yorubas formed the highest respondents (70.8%) 
in the public facility as against (36.1%) it formed 
in private facility. There was statistically 
significant difference in their ethnicity.
 Providers in the public facility were 
predominantly (64.9%) doctors while a lesser 
proportion (39.5%) in the private facility were 
doctors and there was statistically significance 
difference in their professional category. 
Table 2 showed that Less than one-third 
(31.6%) in public and (31.1%) in private still used 
Chloroquine, Daraprin and Paludrine in 
provision of chemoprevention of malaria in 
pregnancy without IPTp, there is no statistically 
significant difference in their choice. In the 
reason for their choice (22.8%) of public and 
(24.4%) of private providers believe it is 
effective.
No statistically significant difference in 
their belief. In the public facilities (72.5%) of the 
providers have provided less than 50 pregnant 
women with chemoprophylaxis in the past one 
month and (82.5%) of the private providers also 
provided less than 50 pregnant women with 
chemoprophylaxis in the past one year. This is 
followed by (17.0%) in the public and (15.1%) in 
private that have seen between 51 to 100 pregnant 
women, while (10.5%) in public and (2.5%) in 
private that have seen above 100 pregnant women 
in the past one month. The mean number of 
pregnant women seen in the past one month was 
59.03 + 75.60 and 40.88 + 40.43  by public and 
private providers respectively. There was 
statistically significant difference in the mean 
number of pregnant women seen by both 
providers (p<0.05).
Table 2b showed that majority (69.0%) 
of public providers and (74.8%) of private 
p r o v i d e r s  p r e s c r i b e  
s u l p h a d o x i n e / p y r i m e t h a m i n e  f o r  
chemoprophylaxis of MIP. This is followed by 
ACT which formed (28.7%) in public and 
(29.4%) in private facilities while Chloroquine, 
Quinine and Artemisinin monotherapy formed 
(19.3%, 12.9% and 11.7%) respectively in public 
and (17.6%, 1.7% and 10.1%) respectively in 
private. There was no statistically significant 
difference in their choice of drugs. 
Table 3 showed that majority (93.6%) of 
public and (99.2%) of private confirmed that they 
used IPTp as preventive strategy. There was 
statistically significant difference in their usage 
(p<0.05). For those not using it, among public 
providers, 1.8%, 0.6% and 0.6% respectively  
said that hospital did not enforce, it was-  a newly 
introduced treatment and absence of IPTp, 
manual, as reasons for not using IPTp . There was 
no statistically significant difference in their 
reason. Less than half (47.4% and 33.6%) in both 
public and private providers strongly agreed that 
IPTp should be taken under observation of health 
officer. There was no statistically significant 
difference in their belief.
Table 3b showed that more (71.9%) of 
the public providers than (57.15) of the private 
provider ensured that women take the drugs in the 
health facility. There was statistically significant 
difference (p<0.05). Reason for not ensuring that 
the women take their drug in health facility 
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(17.0%) of the public providers believe that the 
patients were aware of the danger of malaria in 
pregnancy as against (8.4%) of private providers 
who have the same belief, while (11.7%) of 
public providers and (12.6%) of private providers 
complained of too many patients (work 
overload). There was statistically significant 
difference in their reasons.
Table 3c showed that the mean number of 
patient provided with IPTp in both public and 
private facilities were 113.84+261.79 and 
59.74+101.28 respectively. There was 
statistically difference p=<0.05.
Majority (70.2%) in public and (69.8%) 
in private providers commonly dispensed 
sulphadoxine/pyrimethamine for IPTp. This is 
followed by ACT which revealed (28.1%) in 
public and (30.3%) in private providers while 
chloroquine tablets formed (14.0%) in public and 
(15.1%) in private providers. There was 
statistically significance difference in their 
choice of drugs.
DISCUSSION
This study is a comparative, cross-
sectional, study which was conducted in Lagos 
State to compared the chemoprophylaxis of 
malaria in pregnancy (MIP) by public and private 
secondary antenatal care (ANC) service 
providers in Lagos State. 
The majority (84.2%) of the providers in 
the public facilities were between the ages of 20-
29 years while the private facilities had 64.7% 
respondents who fell within this age group. The 
mean ages in the public and private providers 
were 35.08±7.5 and 33.9 ±10.8 years 
respectively. There was no significant difference 
in the mean age of the groups. This is not in 
keeping with a study in Enugu of which the mean 
 
age was 28.5±4.6 (16). Of the providers in the 
public facilities 77.8% were Christians while 
96.6% of providers in the private facilities 
practiced Christianity. This is keeping with a 
 study in Lagos (15). As expected of a Western 
state, the majority of the respondents were of the 
Yoruba tribe with 70.8% in the public and 36.1 % 
in the private facility being of the Yoruba tribe. 
Low percentage of Yorubas in private facility 
could be that as a Western state, they are to be 
considered f irs t  in s tate  government 
employment. This is in keeping with the study in 
Ibadan where majority of the providers were 
 Yorubas (13).
More of the respondents in the public 
facilities have practiced between 1 to 10years 
(69.5%) while 10.9% of those in private were 
within the same year of practice. The mean years 
of practice in both public and private providers 
were 9.05 ± 7.92 and 9.18±9.9~) respectively. 
There was no statistically significant difference 
in their mean years of practice (p =0.902). The 
largest proportion in both cases (42.7%) in 
public and (26.7%) in private providers were 
medical officers. There was a statistically 
significant difference in the rank of the health 
providers.  
The private providers were more aware 
of the timing (recommended time to give IPTp) 
of IPTp and this was not significant. This is in 
keeping with the study in Enugu where the 
private providers were more aware of the timing 
than the public providers (6). The proper timing 
is very important so as to have full benefits of the 
policy which should be at least two or three times  
-during pregnancy (9). Proper timing with 3 or 
more doses of sulphadoxine-pyrimethamine was 
associated with higher birth weight and lower 
risk of low birth weight than the standard 2 dose 
regimens (12). 
A higher proportion of private providers agreed 
that daily and weekly chemoprophylaxis using 
daraprin, chloroquine and proguanil was still  in 
use and very beneficial compared to the public. 
This is in agreement with the study in Enugu 
which obtained the same result (6). This is not in 
conformity with literature as the daily and 
weekly chemoprophylaxis have been replaced 
with intermittent preventive treatment of malaria 
in pregnancy (IPTp) using sulphadoxine 
/pyrimethamine (1,5).
In recommended drug of choice for IPTp 
majority of the providers in the private and public 
facilities used sulphadoxine-pyrimethamine 
while some in both public and private facilities 
used ACT and some Artesunate/ Artemisinin 
monotherapy. This is in keeping with a study in 
Enugu with 90% in private and 82.1 % in public 
(6) but in contrast with another study carried out 
at the 68 Nigeria Army Reference Hospital Yaba, 
Lagos where only 3.7% of the cases reviewed 
received sulphadoxine-pyrimethamine (15). 
A little above half in both public and 
private providers knew the correct interval 
between doses of IPTp which is one month apart, 
this is in keeping with a study done in Ibadan in 
which only half of the respondents were aware of 
the correct timing (13). The implication of not 
c o n f o r m i n g  t o  c u r r e n t  p r a c t i c e s  i n  
chemoprophylaxis in pregnancy included 
increased foetal, perinatal and maternal 
morbidity and mortality from malaria (13). 
More (32.8%) of the private providers 
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agreed that daily and weekly chemoprophylaxis 
using Daraprin, Chloroquin and Proguanil was 
still in use and very useful compared to (32.2%) 
of the public providers. This is  in contrast with 
the current WHO guideline that adopted IPTp 
with sulphadoxine-pyrimethamine as the gold 
standard for prevention of malaria in pregnancy 
(2).  In 1998, it was proposed, then finally 
implemented in 2004, that weekly or daily 
chemoprophylaxis should no longer be 
recommend, but replaced by intermittent 
preventive treatment for all pregnant women 
living in areas of stable malaria transmission 
(1,2). And Nigeria adopted IPTp as a strategy in 
2005 to replace weekly prophylaxis (5). More of 
the public providers considered IPTp very useful 
as against the private providers and this is in 
contrast with the study done in Enugu where 
more of the private providers than the public 
providers considered IPTp more useful (6). 
Less than half of both public and private 
providers strongly agreed that IPTp should be 
taken under observation of health officer. 
However, more of the public providers ensure 
that the women take the drugs in health facility 
than the private providers and this was significant 
(p=0.012). This did not quite agree with the 
conclusion made in the study conducted in Enugu 
(6) where they found that the private providers 
practice direct observation of patient taking the 
drug in the facility than the public. 
However, some of the providers both in 
private (42.9%) and public (28.1 %) still give IPT 
–Sulphadoxine-pyrimethamine unsupervised 
(without direct observation) with the reasons that 
some women do not eat before coming to ANC, 
while some insists that the patients are aware of 
the danger of MIP, some complained of work 
load, some said this awareness talk given to 
patient are enough while others complained on 
laxity in enforcing the regulation as there's no 
direct supervision arrangement on ground. 
The public providers provided IPTp 
more to the pregnant women compared to private 
providers. The mean number of patient provided 
with IPTp in both public and private facilities 
were 113.84 ± 261.79 and 59.74 ±101.28 
respectively. This was significant (p=0.033). This 
is in keeping with the study done in Enugu (4) 
where such result was also obtained. 
On the choice of drug for IPTp, majority 
of the public and private provider used 
sulphadoxine-pyrimethamine as IPTp  though 
some providers both in public and private used 
ACT, chloroquine, septrin, clindamycin  (as 
adjunct). This is in contrast to a study carried out 
in Enugu (14) where one tenth of Nigerian 
obstetricians surveyed do not routinely 
prescribed IPTp during pregnancy. Also, not in 
keeping with another study at 68 Army Hospital 
Lagos where IPT -SP was prescribed for only 
3.7% of cases reviewed, and all received just one 
dose (15). The fact that some of the providers 
both in private and public facilities still 
prescribed ACT, Chloroquine, Antibiotic 
(septrin), Pyrimethamine,Quinine,  as IPTp, 
shows that the providers may not be fully 
acquainted with the concept of IPT using 
sulphadoxine-pyrimethamine (IPT -SP). 
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CONCLUSION 
This study revealed some deficiencies in 
chemoprophylaxis for malaria in pregnancy in 
Lagos State, Nigeria. The pattern of 
chemoprophylaxis prescription among 
secondary health care providers in Lagos State 
varied widely among the practitioners which 
does not fully embraced the evidence based 
recommendation of the World Health 
Organization Guideline. The public providers 
had a better practice and provision of 
chemoprophylaxis. That only 70.2% of public 
providers and 69.8% of private providers 
prescribed IPT-Sulphadoxine-Pyrimethamine of 
malaria revealed again that public providers have 
better practice of IPTp than private providers.
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Table 1: Socio-demographic characteristics of Healthcare Providers  
                                                                                                                                         
 
Variables 
Public facility (171) 
No  (%) 
Private facility (119)  
No  (%) 




2    (1.2) 
 
18  (0.84) 
   
25-34 years 98  (57.3) 61  (51.26)    
35-44 years 46  (26.9) 16  (13.45)    
45-54 years 23  (13.5) 15  (12.61)    
55 years and above 2   (1.2) 9   (0.84)    
Mean age 35.08 + 7.57 33.97  + 10.82   0.308 
 
Mariral Status 
     
Married 123  (71.9) 72  (60.5) 4.159 1 0.043* 
Single 48   (28.1) 47  (39.5)    
 
Religion 
     
Christianity 133  (77.8) 115  (96.6) 20.154 1 0.000* 
Islam 38   (22.2) 4     (3.4)    
 
Ethnic Group 
     
Hausa 2    (1.2) 1   (0.8) 35.167 3 0.000*** 
Igbo 35   (20.5) 55  (46.2)    
Yoruba 121  (70.8) 43  (36.1)    
Others 13   (7.6) 20  (16.8)    
 
Gender 
      
Male 86  (50.3) 28  (23.5) 21.067 2 0.000* 
Female 85  (49.7) 91  (76.5)    
 
Professional category 
     
Medical doctor 111  (64.9) 47  (39.5) 18.279 2 0.000* 
Nurse 60   (35.1) 72  (60.5)    
 
***fischer exact p-value, *Statistically significant 
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Public facility (171)  
No    % 
Private facility (119)  
No   % 
X2 df p-value 
Years of Practice      
Less than 1 year 5    (2.9) 64   (53.8)    
1-5 years 63   (36.8) 8     (6.7)    
6-10 years 56   (32.7) 5     (4.2)    
11-15 years 18   (10.5) 23   (19.3)    
16-20 years 9    (5.3) 18   (15.1)    
More than 20 years 20   (11.7) 1     (0.8)    
Mean 9.05 + 7.92  9.18 + 9.99   0.902 
      
Current Rank      
Consultant 3     (1.8) 6     (5.0) (43.72) 8 0.000*** 
Registrar 8     (4.7) 3     (2.5)    
Medical Officer  73   (42.7) 32   (26.9)    
House Officer 26   (15.2) 8     (6.7)    
Chief Nursing Officer 14   (8.2) 5     (4.2)    
Asst Chief Nursing 
Officer 
3     (1.8) 4     (3.4)    
PNO 12   (7.0) 4     (3.4)    
Sister 24   (14.0) 25   (21.0)    
Staff 8     (4.7) 32   (26.9)    
***Fischer exact p-value *statistically significant 
Table 2: Provision of Chemoprevention of Malaria in Pregnancy Without IPTp 
 
Provision of
Chemoprevention of MIP 
without IPTp 
Public 171 (%) Private 119 (%) X2 df  p-value 
Use of daraprin, chloroquine 
and paludrine   
     
                         Yes 54 (31.6) 37 (31.1) 0.008 1 0.930 
                         No 117 (68.4) 82 (68.9)    
      
Reason for use       
It is effective 39 (22.8) 29 (24.4) 2.654 3 0.427 
Reduces complications in 
pregnancy 
10 (5.8) 6 (5.0)    
Approved by the Government 
and WHO  
 5 (2.9) 2 (1.7)    
Not applicable  171 (68.4) 82 (68.9)    
      
No of women 
chemoprophylaxis  
     
                      0-50 124 (72.5) 98 (82.4)    
                      51-100 29 (17.0) 18 (15.1)    
                      Above 100 18 (10.5) 3 (2.5)    
Mean 59 03 + 75.60 40.88 + 40.43   0.017* 
*Statistically significant 
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Table 2b: Provision of Chemoprevention of Malaria in Pregnancy Without IPTp 
 
Provision of Chemoprevention of 
MIP without IPTp 
Public 171 
(%) 
Private 119  
(%) 
X2 df p-value 
Drugs given for chemoprophylaxis 
of malaria in pregnancy** 
     
Artemisinin-based combination 
therapy 
49 (28.7) 35 (29.4) 11.917 5 0.036 
Sulphadoxine/pyrimethamine 118 (69.0) 89 (74.8)    
Chloroquine 33 (19.3) 21 (17.6)    
Quinine 22 (12.9) 2 (1.7)    
Artemisin/artesunate 20 (11.7) 12 (10.1)    
Others: daraprim, septrin  4 (2.3) 5 (4.2)    
 **multiple response  
Table 3: Provision of Chemoprevention for Malaria in pregnancy with IPTp 
 
Provision of Chemoprevention of 





X2 df  p-value 
Whether IPTp is used as preventive 
strategy 
     
Yes 106 (93.6) 118 (99.2) 0.015 1 0.999*** 
No 11 (6.4) 1 (0.8)    
 
Reason for not using IPTp 
     
The laboratory tells if patients have 
malaria 
2 (1.2) 0 (0.0) 9.244 7 0.247 
Hospital do not enforce it  3 (1.8) 0 (0.0)    
It is a newly introduced treatment 1 (0.6) 0 (0.0)    
Absence if IPTp manual 1 (0.6) 0 (0.0)    
Treats patients symptomatically 2 (1.2) 0 (0.0)    
Unavailable 2 (1.2) 0 (0.0)    
Unknown 0 (0.0) 1 (0.8)    
Not applicable 162 (94.8) 118 (99.2)    
 
Best time to give IPTp 
     
First trimester 29 (17.0) 31 (26.1) 6.869 4 0.125 
Second trimester 108 (63.2) 71 (59.7)    
Third trimester 5 (2.9) 5 (4.2)    
After quickening 0 (0.0) 1 (0.8)    
Not applicable 26 (15.2) 9 (7.6)    
 
IPTp should be under observation 
of health officer 
     
Strongly agree 81 (47.4) 40 (33.6) 7.336 4 0.119 
Agree 36 (21.1) 39 (32.8)    
Disagree 18 (10.5) 15 (12.6)    
Indifferent 32 (18.7) 23 (19.3)    
Strongly disagree 4 (2.3) 2 (1.7)    
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Table 3b: Provision of Chemoprevention for Malaria in pregnancy with IPTp 
 
Provision of Chemoprevention of 





X2 df  p-value 
Provision of direct observed IPTp      
Yes 123 (71.9) 68 (57,1) 6.824 1 0.012* 
No 48 (28.1) 51 (42.9)    
 
Reasons for saying “no” 
     
Some don’t eat before coming for 
ANC 
3 (1.8) 7 (5.9) 11.822 9 0.224 
The patients are aware of the danger 
of malaria in pregnancy 
12 (17.0) 10 (8.4)    
Too many patients 20 (11.7) 15 (12.6)    
Indifferent  0 (0.00) 2 (1.7)    
They can take the drugs at home 3 (1.8) 3 (2.5)    
The patients are mature enough to 
comply 
1 (0.6) 4 (3.4)    
Pharmacists dispense the drugs 1 (0.6) 1 (0.8)    
Patients are given awareness talk 3 (1.8) 8 (6.7)    
It may not be convenient for the 
woman 
2 (1.2) 1 (0.8)    
There’s no direct supervision 
arrangement made 
3 (1.8) 0 (0.00)    
Not applicable 123 971.9) 68 (57.1)    
*Statistically significant 
Table 3c: Provision of Chemoprevention for Malaria in pregnancy with IPTp 
 
Provision of Chemoprevention of 
MIP with IPTp 
Public 171 (%) Private 119 (%) X2 df  p-
value 
No of patient provided with IPTp in 
one month 
     
<50 80 (46.8) 67 (56.3)    
50-100 63 (36.8) 37 (31.1)    
>100 28 (16.4) 15 (12.6)    
Mean 
 
Drug of choice of IPTp 
113.84+261.79 58.74+101.28   0.033
* 
Artemisin-based combination therapy 48 (28.1) 36 (30.3) 14.048 8 0.081 
Sulphadoxine/pyrimethamine 120 (70.2) 83 (69.8)    
Chloroquine injection 16 (9.4) 7 (5.9)    
Chloroquine tablets 24 (14.0) 18 (15.1)    
Antibiotics: septrin,clindamycin 8 (4.7) 11 (9.2)    
Quinine 18 (10.5) 4 (3.4)    
Artemisin/artesunatemonotherapy 12 (7.0) 7 (5.9)    
Proguanil 19 (11.1) 20 (16.8)    
Pyrimethamine 11 (6.4) 17 (14.3)    
Others: none 0 (0.0)     
 
Chemoprophylaxis for malaria in pregnancy                                                            Akodu et al.
